DNAzyme 10-23 - Based Nanomachines for Nucleic Acid Recognition
February 9th, 2024
The DNAzyme-based nanomachines can be used for highly selective and sensitive detection of nucleic acids. This article describes a detailed protocol for the design of DNAzyme-based nanomachines with a 10-23 core using free software and their application in the detection of an Epstein-Barr virus fragment as an example.
Overview
This article discusses the development of DNAzyme-based nanomachines for the selective and sensitive detection of nucleic acids. It provides a detailed protocol for designing these nanomachines using free software, exemplified by their application in detecting an Epstein-Barr virus fragment.
Key Study Components
Area of Science
- Biotechnology
- Molecular Biology
- Nanotechnology
Background
- DNAzymes are synthetic nucleic acid enzymes.
- They can catalyze specific biochemical reactions.
- Previous advancements have improved their selectivity and sensitivity.
- Challenges remain in enhancing their performance compared to traditional methods.
Purpose of Study
- To design DNAzyme-based nanomachines for nucleic acid detection.
- To demonstrate their application in detecting viral fragments.
- To address sensitivity and selectivity issues in DNA sensors.
Methods Used
- Design of DNAzyme-based nanomachines using free software.
- Application of the designed nanomachines in detecting Epstein-Barr virus fragments.
- Evaluation of sensitivity and selectivity in comparison to conventional methods.
- Utilization of multi-component binding arms for complex targets.
Main Results
- Successful design of DNAzyme-based nanomachines.
- Demonstrated high selectivity in detecting nucleic acids.
- Identified challenges in sensitivity compared to amplification techniques.
- Proposed new molecular designs to enhance performance.
Conclusions
- DNAzyme-based nanomachines show promise for nucleic acid detection.
- Further improvements are needed to enhance sensitivity and selectivity.
- Future work will focus on overcoming current limitations.
Frequently Asked Questions
Executive Industry Relevance
DNAzyme 10-23-based nanomachines enable highly selective and sensitive nucleic acid recognition, addressing critical challenges in early-stage molecular diagnostics and target validation. Their ability to discriminate single nucleotide differences and detect analytes at extremely low concentrations supports predictive confidence in biomarker discovery and assay development. These protein-free, modular constructs offer scalable, reproducible solutions for nucleic acid detection workflows across discovery and translational research pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of nucleic acid targets with single-nucleotide specificity for robust target validation.
- Supports biological de-risking by distinguishing closely related genetic variants in complex samples.
- Facilitates predictive confidence in early biomarker identification and portfolio triage.
Screening & Assay Development
- Prepares validated nucleic acid detection systems for downstream high-throughput screening workflows.
- Delivers quantitative, fluorescence-based outputs for standardized assay development.
- Enables reproducible, scalable detection of DNA and RNA analytes without protein enzymes.
- Supports reliable evaluation of molecular probes and diagnostic candidates.
Translational & Preclinical Research
- Aligns with translational biomarker strategies by enabling detection of disease-relevant nucleic acid signatures.
- Provides continuity from discovery through preclinical validation with modular, chemically accessible probes.
- Reduces mechanistic ambiguity in nucleic acid-based diagnostic development.
Pipeline & Workflow Integration
DNAzyme-based nanomachines integrate into the discovery-to-preclinical continuum as a reusable platform for nucleic acid recognition, supporting workflows from hypothesis testing to lead identification and translational biomarker validation.
- Discovery Biology: Advances hypothesis testing and pathway clarification by enabling precise nucleic acid target interrogation.
- Screening: Delivers assay-ready, quantitative fluorescence outputs for comparative analysis of probe performance.
- Analytics: Provides sensitive, reproducible measurements for cross-condition and cross-sample comparisons.
- Translational Research: Supports biomarker alignment and preclinical continuity with protein-free, modifiable probes.
- Enterprise Reuse: Offers a modular, scalable detection capability adaptable across diverse nucleic acid targets and model systems.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in nucleic acid detection.
- Operational Value: Enables standardization, reproducibility, and scalability in assay workflows.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by reducing late-stage biological risk.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of diagnostic and biomarker programs.
Implementation Considerations
- Requires expertise in nucleic acid design, folding analysis, and fluorescence-based detection.
- Needs access to oligonucleotide synthesis, PAGE analysis, and fluorescence plate readers.
- Demands cross-team standardization of probe design and assay conditions for reproducibility.
- Adaptable to various nucleic acid targets and compatible with chemical modifications.
- Current sensitivity may be lower than amplification-based methods, requiring ongoing optimization.
Biopharma FAQs
Chapters in this video
0:00
Introduction
2:38
Designing DNAzyme‐Based Nanomachines with a 10‐23 Core for Detection of an Epstein‐Barr Virus Fragment
4:30
Assembly of DNAzyme‐Based Nanomachines for its Functional Characterization
5:59
Limit of Detection (LOD) Assay to Check the Sensitivity of DNAzyme-Based Nanomachines (DNM)
